EnginZyme inks Series A
Stockholm-based EnginZyme, a cell-free synthetic biology company, has secured 6.4 million euros in Series A funding.
Stockholm-based EnginZyme, a cell-free synthetic biology company, has secured 6.4 million euros in Series A funding.
Copyright PEI Media
Not for publication, email or dissemination